StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a report released on Thursday morning. The firm issued a sell rating on the stock.

Oragenics Price Performance

OGEN opened at $0.28 on Thursday. The business has a 50 day moving average price of $0.33 and a two-hundred day moving average price of $0.59. The company has a market capitalization of $3.47 million, a price-to-earnings ratio of -0.04 and a beta of 0.40. Oragenics has a 1-year low of $0.25 and a 1-year high of $5.14.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.